Axsome Therapeutics, Inc. $AXSM Shares Sold by Blair William & Co. IL

Blair William & Co. IL lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 5.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,482 shares of the company’s stock after selling 3,047 shares during the period. Blair William & Co. IL owned about 0.10% of Axsome Therapeutics worth $5,165,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of AXSM. Caitong International Asset Management Co. Ltd acquired a new position in shares of Axsome Therapeutics in the first quarter worth about $25,000. Quantbot Technologies LP acquired a new position in shares of Axsome Therapeutics in the first quarter worth about $31,000. AlphaQuest LLC acquired a new position in shares of Axsome Therapeutics in the first quarter worth about $38,000. Neo Ivy Capital Management acquired a new position in shares of Axsome Therapeutics in the first quarter worth about $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Axsome Therapeutics in the first quarter worth about $47,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 12,774 shares of the company’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $118.84, for a total transaction of $1,518,062.16. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $859,094.36. This represents a 63.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Mark L. Jacobson sold 10,000 shares of the company’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total transaction of $1,159,600.00. The disclosure for this sale can be found here. Insiders sold a total of 243,332 shares of company stock worth $28,824,746 in the last 90 days. 22.30% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Down 0.7%

Shares of NASDAQ AXSM opened at $121.71 on Monday. Axsome Therapeutics, Inc. has a 12-month low of $75.56 and a 12-month high of $139.13. The stock has a market cap of $6.07 billion, a PE ratio of -24.01 and a beta of 0.52. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The company has a 50-day moving average of $116.84 and a 200 day moving average of $109.84.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $150.04 million during the quarter, compared to analysts’ expectations of $140.02 million. As a group, sell-side analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on AXSM shares. Bank of America upped their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Needham & Company LLC reissued a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Wells Fargo & Company raised shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 3rd. B. Riley initiated coverage on shares of Axsome Therapeutics in a research note on Wednesday, October 1st. They set a “buy” rating and a $179.00 target price for the company. Finally, Royal Bank Of Canada boosted their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $177.93.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.